key: cord-0776125-xse0tqxu
authors: Lin, Chien-Jung; Mecham, Robert P.; Mann, Douglas L.
title: RNA Vaccines for COVID-19: Five Things Every Cardiologist Should Know
date: 2020-11-23
journal: JACC Basic Transl Sci
DOI: 10.1016/j.jacbts.2020.11.006
sha: 1fc71e5b29e29e3ea6cd5dcee2e503c7eae30643
doc_id: 776125
cord_uid: xse0tqxu

[Figure: see text]

The development of a safe and effective vaccine against SARS-CoV-2 is critical for ensuring worldwide public health, as well as potentially ending the COVID-19 pandemic. Four vaccine candidates are currently in phase 3 trials in the United States (Table 1) , with many more ongoing internationally. These vaccines were developed using various technology platforms, including RNA, DNA, recombinant protein, inactivated virus, live attenuated virus, and vector-dependent vaccines (1) . There was tremendous excitement in November when both Pfizer and Moderna announced encouraging preliminary results of >90% efficacy with their RNA vaccine candidates against SARS-CoV-2. Insofar as RNA vaccines are relatively new and may be unfamiliar to the cardiovascular community, here, we will briefly review five things that cardiologists should know about COVID-19 RNA vaccines so that they are better prepared to care for their patients.

Traditional vaccines utilize pathogens (live, attenuated, or inactivated), their components (recombinant protein, subunit, polysaccharide or conjugate), or toxins (toxoid) to elicit host immune responses. While these approaches provide durable protection against various diseases and have had significant public health benefits, their major limitation in the current global pandemic is that they can be challenging to develop and manufacture at scale quickly. RNA vaccines, on the other hand, provide a platform that can be designed and mass-produced rapidly.

Although no RNA vaccines have been approved to date for human use, several are in clinical trials, most notably two candidates targeting SARS-CoV-2 from Moderna (mRNA-1273) and

Pfizer/BioNTech (BNT162b2). Preclinical studies established that antibodies binding to the spike protein, primarily its receptorbinding domain, neutralize the virus by preventing it from binding to ACE2 on host cells. The synthetic mRNAs are modified so that they can be efficiently translated by the cellular translation machinery. The nascent translated protein undergoes post-translational modifications and can be secreted, or alternatively presented on the cell surface by the cell's major histocompatibility complex (MHC I), which allows the host to mount a targeted immune response directed against the viral protein (2). Foreign RNA also stimulates the innate immune system (interferon type I response) that, in turn, boosts the adaptive immune response. After translation, the synthetic mRNA is degraded by host enzymes so that it does not interact with the host genome.

The RNA vaccine approach has several practical advantages. First, RNA can be produced in the laboratory from a DNA template, using readily available materials that are faster to prepare than conventional vaccine production requiring the use of chicken eggs or other mammalian cell expression systems engineered to produce protein antigens. With RNA vaccines, the specific amino acid sequence that determines the antigenic protein's immune specificity can be easily adapted to the pathogen's genetic code. This inherent versatility has contributed to the J o u r n a l P r e -p r o o f unprecedented speed of a candidate vaccine entering a Phase 1 trial (3/16/20 for Moderna's mRNA-1273), less than ten weeks after the viral genome sequence became available (on 1/10/2020).

RNA vaccines, however, are not without potential shortcomings. Since no RNA vaccine has yet been approved, we do not know the long-term safety and efficacy of this new technology. (3, 4) . Fever/chills are reported in 40-60% of study participants in both phase 1 trials. Almost all participants reported some systemic symptoms after two doses. However, the reported adverse events (fatigue, fever, chills, headache, myalgia, nausea, and pain) are mostly (>80%) mild or moderate and are generally similar to side effects from other vaccine classes (https://www.cdc.gov/vaccines/vac-gen/side-effects.htm). Of note, side effects from the RNA vaccines do not appear to include common cardiopulmonary symptoms such as chest pain, dyspnea, lower extremity swelling, or palpitations. It is also important to recognize that the safety issues that temporarily halted COVID-19 vaccine trials were not associated with either of the lead RNA vaccine candidates (Table 1) . From a long-term safety perspective, RNA vaccines appear to be safe; since they are not made with pathogens, they are non-infectious. Further, synthetic mRNAs do not integrate into the host genome, so the risk of long-term mutations in host DNA should not occur. However, one of the unintended consequences of RNA vaccines is that the foreign mRNA strands may elicit an unintended immune reaction (interferon type I response), leading to fevers/chills. These reactions can be minimized by modification and purification of the RNA molecules during manufacturing.

There are currently no approved RNA vaccines for use in humans. Accordingly, the risk and safety profile of RNA vaccines in different groups of individuals remains unclear. Subgroup analysis from a larger data set and post-marketing surveillance may be required. Furthermore, both ongoing RNA vaccine Phase 3 trials excluded pregnant or breastfeeding women, immunocompromised/immunosuppressed patients, and children < 12 years of age (< 18 years for mRNA-1273). As noted above, some mRNA vaccine platforms induce potent type I interferon J o u r n a l P r e -p r o o f responses associated with inflammation and the potential to develop autoimmunity. Further study will be required to define the safety and efficacy of RNA vaccines in vulnerable populations.

Another unknown is whether the immune response with RNA vaccines will confer long term immunity against SARS-CoV-2 or whether the protection will be short lived. Pfizer/BioNTech's BNT162b2 is also a lipid nanoparticle-formulated, nucleosidemodified RNA vaccine. The RNA encodes full-length viral spike protein, whereas its cousin candidate BNT162b1 encodes the spike protein's receptor-binding domain. BNT162b2 outperformed BNT162b1 in its safety profile. The Phase 2/3 trial was also started on 7/27/20 and is a 120-site international study with a majority of subjects from the U.S (NCT04368728). The vaccine is given intramuscularly in 2 doses three weeks apart. Over 43,000 subjects have been J o u r n a l P r e -p r o o f enrolled. Reportedly, 42% of enrolled individuals globally and 30% in the U.S. are from racially diverse backgrounds. The primary efficacy endpoint is confirmed COVID-19 diagnosis seven days after the second dose. On 11/9/20, an interim analysis of 94 confirmed cases revealed the vaccine to be 90% effective. After a median follow-up of 2 months, the safety data are expected by the third week of November 2020.

The FDA requires COVID-19 vaccines to be at least 50% more effective than placebo, comparable to flu vaccines over the last decade (efficacy ranging from 19%-60%). In contrast, the World Health Organization has set a higher benchmark of 70% efficacy and protection duration for one year. The >90% efficacy reported by both developers in their interim analyses clearly meets and exceeds worldwide regulatory efficacy standards if confirmed in the full trial results. To ensure a vaccine's safety, the FDA also mandates a median follow-up of 2 months after the last vaccine dose to assess a vaccine's risk-benefit profile. Pfizer expects to report its data by the third week of November 2020, while Moderna's is expected a few weeks after. At that point the companies will seek Emergency Use Approval (EUA) from the FDA, which will allow for immediate use of the vaccine. Operation Warp Speed (OWS) is a partnership between the Department of Health and Human Services, the Department of Defense, and the private sector that aims to deliver 300 million doses of COVID-19 vaccines by January 2021. OWS has been providing support to vaccine developers to expedite their research and development. By mass-producing the vaccines while being tested, the timeline between the demonstration of efficacy and the vaccines' availability is greatly diminished (5) . The Department of Defense is providing logistical support and will facilitate the distribution of the vaccine. Vaccines will only be effective if people are willing to be vaccinated. Given the politicization of the COVID-19 pandemic, it is not at all surprising that many people may be hesitant to receive an FDA-approved vaccine, let alone a type of vaccine that has never been used before in humans. To this end, we hope that this brief primer will be useful to cardiologists who are caring for patients during the pandemic and who may be asked by their patients whether they should take the vaccine against SARS-CoV-2.

J o u r n a l P r e -p r o o f 

SARS-CoV-2 vaccines in development

mRNA vaccines -a new era in vaccinology

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Developing Safe and Effective Covid Vaccines -Operation Warp Speed's Strategy and Approach